-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to data, in 2021, the FDA approved a total of 50 innovative treatments (53 in the same period last year)
In this regard, the industry believes that from the above data, it can be clearly seen that the industry is currently enthusiastic about the research and development of innovative therapies
In addition to the above-mentioned drugs, it is worth mentioning that, according to the statistics of the "Nature" journal report, 18 innovative treatments will be launched in 2022 and are worthy of attention
The industry believes that the reason why innovative therapies have become the current research and development focus of pharmaceutical companies is that it is easier for innovative therapies to obtain special qualifications from the FDA, which can speed up the review of therapies; and innovative therapies are the treatment of patients with specific genetic variants.
It is worth mentioning that, on the whole, CAR-T and ADC have become the main focus of pharmaceutical companies in innovative therapies
According to data, domestic pharmaceutical companies have been actively deploying CAR-T cell therapy drugs in recent years
In addition, ADC is also a therapy that has received a lot of attention